Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells
Cancer Reports · 2024
DOI: 10.1002/cnr2.2075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Mohammad Mahbubul Hoque und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Pancreatic Neoplasms, Cellular Senescence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST SPRING, JSPS KAKENHI.
Abstract (Originalsprache)
Introduction
Gemcitabine (GEM) is often used to treat pancreatic cancer. Many anti‐cancer drugs induce cancer cell death, but some cells survive after cell cycle arrest. Such a response to DNA damage is termed cellular senescence. Certain drugs, including the Bcl‐2‐family inhibitor ABT‐263, kill senescent cells; this is termed senolysis. In this study, we examined the therapeutic benefits of ABT‐263 in GEM‐induced senescence of human pancreatic cancer cells. Methods and Results Of four pancreatic cancer cell lines (PANC‐1, AsPC‐1, CFPAC‐1, and PANC10.05), GEM induced senescent features in PANC‐1 and AsPC‐1 cells, including increases in the cell sizes and expression levels of mRNAs encoding interleukin (IL)‐6/IL‐8 and induction of β‐galactosidase. Successive treatment with GEM and ABT‐263 triggered apoptosis in PANC‐1 and AsPC‐1 cells and suppressed colony formation significantly. Senolysis of GEM‐induced senescent pancreatic cancer cells by ABT‐263 was triggered by a Bcl‐xL inhibitor, but not by a Bcl‐2 inhibitor, suggesting a central role for Bcl‐xL in senolysis. In a xenograft mouse model, combined treatment with GEM and ABT‐737 (an ABT‐263 analog exhibiting the same specificity) suppressed in vivo growth of AsPC‐1 significantly.
Conclusion
Together, our results indicate that sequential treatment with GEM and senolytic drugs effectively kill human pancreatic cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
ORCID-Profile: Mamoru Harada
Förderung
- JST SPRING
- JSPS KAKENHI
Zitieren
APA
Hoque, M. M., Iida, Y., Kotani, H., & Harada, M. (2024). Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells. Cancer Reports. https://doi.org/10.1002/cnr2.2075
Vancouver
Hoque MM, Iida Y, Kotani H, Harada M. Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells. Cancer Reports. 2024. doi:10.1002/cnr2.2075
BibTeX
@article{Hoque2024,
author = {Hoque, Mohammad Mahbubul and Iida, Yuichi and Kotani, Hitoshi and Harada, Mamoru},
title = {Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2075}
}
EUVIMED